Quarterly Result29 May 2026, 08:14 pm
Welcure Drugs: Audited Standalone Financial Results for FY26
AI Summary
Welcure Drugs & Pharmaceuticals Ltd announced the audited standalone financial results for the quarter and year ended March 31, 2026. The board of directors approved the results in a meeting held on May 29, 2026. The auditor's report contains an unmodified opinion but raises concerns regarding trade receivables, payables, loans, advances, and inventory valuation.
Key Highlights
- Audited standalone financial results for the quarter and year ended March 31, 2026, approved.
- Auditor's report includes an unmodified opinion.
- Concerns raised regarding trade receivables, payables, and loans.
- MSME creditor bifurcation not provided, impacting regulatory compliance.
- Lack of E-Way bills and delivery challans for certain sales invoices.
Price Impact
More from WELCURE